The Lancet

Is partial complement blockade enough in myasthenia gravis?

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
The Manila Times

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG ...

Cutting calories to slow aging—without compromising health

Restricting calorie intake in species such as mice, rhesus monkeys, and fruit flies has been shown to extend their lifespans.
Knowridge Science Report

Scientists find safer treatment for chronic inflammation

Our immune system works all the time to protect us from harmful bacteria, viruses, and injuries. It is a complex system made ...

Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

EMPAVELI®(pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in CanadaApproval supported ...

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan ...
Everyday Health

Understanding the ‘C3’ in C3G: Your Guide to Monitoring Complement Activity

C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...
The Next Web

How an AI system beat experienced doctors at diagnosing rare diseases

DeepRare, an agentic AI system integrating 40 specialised tools, outperformed medical specialists in identifying rare conditions in a head-to-head study published in Nature. For millions of people ...
Boston Herald

FDA proposes new system for approving customized drugs and therapies for rare diseases

WASHINGTON (AP) — Federal health officials on Monday laid out a proposal to spur development of customized treatments for patients with hard-to-treat diseases, including for rare genetic conditions ...
CNN

FDA proposes new system for approving customized drugs and therapies for rare diseases

Federal health officials on Monday laid out a proposal to spur development of customized treatments for patients with hard-to-treat diseases, including for rare genetic conditions that the ...
Seeking Alpha

Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Annexon offers high-risk, high-reward potential with its C1q-targeted pipeline, led by tanruprubart for GBS and vonaprument for geographic atrophy. Tanruprubart’s Phase III results are promising, but ...
verywellhealth

6 Types of Treatment for Complement 3 Glomerulopathy

Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...